Tumors Clinical Trials

912 recruitingLast updated: July 25, 2026

There are 912 actively recruiting tumors clinical trials across 60 countries. Studies span Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 3, Phase 4. Top locations include Houston, Texas, United States, Beijing, Beijing Municipality, China, New York, New York, United States. Updated daily from ClinicalTrials.gov.


Tumors Trials at a Glance

912 actively recruiting trials for tumors are listed on ClinicalTrialsFinder across 6 cities in 60 countries. The largest study group is Phase 1 with 541 trials, with the heaviest enrollment activity in Houston, Beijing, and New York. Lead sponsors running tumors studies include National Cancer Institute (NCI), Cancer Institute and Hospital, Chinese Academy of Medical Sciences, and Suzhou Suncadia Biopharmaceuticals Co., Ltd..

Treatments under study

About Tumors Clinical Trials

Looking for clinical trials for Tumors? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Tumors trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Tumors clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 912 trials

Recruiting
Phase 1Phase 2

A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors

Solid Tumors
Shanghai Shengdi Pharmaceutical Co., Ltd258 enrolled1 locationNCT07231211
Recruiting
Phase 2

A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

Solid TumorsLymphoma
Spectrum Pharmaceuticals, Inc40 enrolled5 locationsNCT04570423
Recruiting
Phase 1

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

Colorectal, CancerPancreatic CancerGastric Cancer+1 more
ArriVent BioPharma, Inc.405 enrolled20 locationsNCT07066657
Recruiting
Phase 1

Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma

Advanced Solid TumorsRelapsed/Refractory B-cell Lymphoma
InSilico Medicine Hong Kong Limited60 enrolled4 locationsNCT06445517
Recruiting
Phase 1

First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors

Solid Tumors (Phase 1)
Adcendo ApS180 enrolled7 locationsNCT07362888
Recruiting
Phase 1Phase 2

An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors

Neuroendocrine Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences40 enrolled1 locationNCT06038461
Recruiting

NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors

Solid TumorOther Solid TumorsVery Rare Tumors+2 more
National Cancer Institute (NCI)4,000 enrolled1 locationNCT07489378
Recruiting

Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors

Non-small Cell Lung CancerSmall Cell Lung CancerExtrapulmonary Small Cell Cancer+2 more
National Cancer Institute (NCI)2,000 enrolled1 locationNCT02146170
Recruiting
Phase 2

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

Neuroendocrine CarcinomaCarcinoma, NeuroendocrineTumor, Neuroendocrine+2 more
National Cancer Institute (NCI)60 enrolled1 locationNCT06406465
Recruiting
Phase 1

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

Advanced Breast CancerAdvanced Solid TumorsMetastatic Pancreatic Cancer+3 more
National Cancer Institute (NCI)116 enrolled2 locationsNCT04222413
Recruiting
Phase 1

A Study in Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-resistant Prostate CancermCRPC (Metastatic Castration-resistant Prostate Cancer)Prostatic Neoplasms, Castration-Resistant+5 more
Flare Therapeutics Inc.60 enrolled10 locationsNCT07719361
Recruiting
Phase 1Phase 2

Personalized Neoantigen Peptide Vaccines for Solid Tumors

Solid TumorsAdvanced CancerRecurrent Cancer+2 more
Seqker Biosciences, Inc.10 enrolled1 locationNCT07002203
Recruiting
Phase 3

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Solid TumorsHematologic Malignancies
Merck Sharp & Dohme LLC3,500 enrolled781 locationsNCT03486873
Recruiting
Phase 1Phase 2

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

Solid TumorsAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia+6 more
Incyte Biosciences International Sàrl70 enrolled23 locationsNCT03934372
Recruiting
Phase 1

A Study of ASP1002 in Adults for Treatment of Solid Tumors

Advanced Solid Tumors
Astellas Pharma Global Development, Inc.798 enrolled15 locationsNCT05719558
Recruiting
Phase 1Phase 2

A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors

Advanced Solid Tumors
LigaChem Biosciences, Inc.191 enrolled8 locationsNCT07460375
Recruiting
Phase 1

IDOV-Immune for Advanced Solid Tumors

Breast CancerColorectal, CancerEsophageal Cancer+13 more
ViroMissile, Inc.78 enrolled5 locationsNCT06910657
Recruiting
Phase 2

A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation

Advanced Solid Tumors
Amgen14 enrolled11 locationsNCT07172919
Recruiting
Phase 3

A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

Solid Tumors
Incyte Corporation588 enrolled215 locationsNCT07522073
Recruiting

Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies

SarcomaEndocrine TumorsNeuroblastoma+2 more
National Cancer Institute (NCI)6,035 enrolled5 locationsNCT01109394